Thermo Fisher Scientific and UCSF open cell therapy manufacturing facility
.png)
In collaboration with Thermo Fisher Scientific, UCSF has opened a new manufacturing site aimed at accelerating advanced cell and gene therapies for cancer, rare diseases, and other illnesses.
The University of California, San Francisco and Thermo Fisher Scientific have opened a new cGMP manufacturing facility specialising in advanced cell therapies for the treatment of cancer, rare diseases, and other difficult-to-treat illnesses. The facility sits adjacent to the UCSF Medical Center’s Mission Bay campus.
First announced in 2021, the partnership between Thermo Fisher and UCSF will enable scientists, clinicians, and patients closer access to a manufacturing site, and potentially demonstrate how the development of breakthrough treatments may be expedited with increased access to state-of-the-art facilities. The initial focus of the site will be the development of treatments for glioblastomas, multiple myeloma, and other forms of cancer utilising updated approaches on CAR T and CRISPR technologies.
Executive VP and COO of Thermo Fisher Michel Lagarde stated: “Cell therapies represent a rapidly emerging field of biotechnology with tremendous promise for future therapeutic applications. With a record number of cell therapy approvals granted in the last 2 years, and CAR-T therapies becoming earlier treatment options, we’re in a golden age of biology where new technologies and partnerships are evolving and transforming clinical care.”
As part of Thermo Fisher’s global network of pharmaceutical and therapeutic services, including over 15 locations servicing cell and gene therapies, the facility will offer the UCSF community and other customers process and analytical capabilities, and clinical and commercial manufacturing services for advanced cell and gene therapies. Drug development, discovery, and commercialisation will also be accessible for those looking to benefit from Thermo Fisher’s therapeutic development capabilities with this San Francisco facility.
UCSF Chancellor, Sam Hawgood, commented on the site establishment: “UCSF is one of the top clinical sites for CAR-T treatment, and our scientists are leading the next generation of CAR-T therapy development. These approaches will be tested soon in patients with solid tumours like glioblastoma and later in other diseases, including autoimmunity.”
Source: Thermo Fisher Scientific Opens Cell Therapy Facility at University of California, San Francisco, to Accelerate Development of Breakthrough Therapies [Accessed March 27 2023] https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2023/Thermo-Fisher-Scientific-Opens-Cell-Therapy-Facility-at-University-of-California-San-Francisco-to-Accelerate-Development-of-Breakthrough-Therapies/default.aspx
Related News
-
News Rebuilding the United States' pharma infrastructure – CPHI North America 2023 preview
As we prepare for CPHI North America from April 25–27 in Philadelphia, USA, CPHI Online caught up with some of the track sponsors to discuss how the show connects vital players within the North American pharmaceutical landscape. ... -
News Digital-first experimental approach to optimise drug formulations
Merck and XtalPi Inc. collaborate on an AI-powered technology platform to predict the crystal morphologies of diabetic medication metformin HCl, validated by wet-lab experiments conducted with Merck’s expertise, in a ‘digital-first’ a... -
News To recruit or to retain - where is the pharma talent going?
Discover how the pharmaceutical workforce has evolved past the pandemic, and the challenges faced by the pharma industry during a talent acquisition and retention crisis. -
News NextPharma acquisition of chewable tablet manufacturing site from Takeda complete
NextPharma has completed their acquisition of a Norway-based manufacturing site, specialising in chewable tablet technologies for calcium/vitamin D3 from pharmaceutical giant Takeda. -
News Doctors Without Borders demands transparency from GSK on licensing agreements for preventative HIV treatment
GSK has signed licensed agreements with three companies to manufacture generic versions of its preventative HIV medicine for distribution in lower-income countries but calls for increased transparency is putting pressure on the drugmaker. -
News 3 ways ChatGPT will impact pharma marketing teams
What does the rise of AI-powered chatbots such as ChatGPT and GPT-4 mean for pharma marketeers? -
News Innovation in Drug Delivery & Portfolio Renovation with Sofgen Pharmaceuticals
The Pharma industry is expected to reach $1.9Tn in revenue by 2027, increasing at a rate of 3-6% per year, according to IQVIA1, with some regions being driven by volume, and others by innovation. Growth in developed economies is projected to be slow, w... -
News Vetter joins United Nations Global Compact Network
Vetter (Ravensbury, Germany), the aseptic filling and packaging CDMO has signed up to the UN Global Compact Network.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance